Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000905148-25-002996·Oric Pharmaceuticals, Inc.
Schedule 13G ownership disclosure
ORIC Pharmaceuticals Inc
Common Stock, $0.0001 par value per share · CUSIP: 68622P109
Event date: 2025-06-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- VIKING GLOBAL INVESTORS LP
Shares: 8,729,345 · Class: 9.99%
- Viking Global Opportunities Parent GP LLC
Shares: 8,729,345 · Class: 9.99%
- Viking Global Opportunities GP LLC
Shares: 5,606,787 · Class: 6.42%
- Viking Global Opportunities Portfolio GP LLC
Shares: 5,606,787 · Class: 6.42%
- Viking Global Opportunities Illiquid Investments Sub-Master LP
Shares: 5,606,787 · Class: 6.42%
- Viking Global Opportunities Drawdown GP LLC
Shares: 3,122,558 · Class: 3.57%
- Viking Global Opportunities Drawdown Portfolio GP LLC
Shares: 3,122,558 · Class: 3.57%
- Viking Global Opportunities Drawdown (Aggregator) LP
Shares: 3,122,558 · Class: 3.57%
- HALVORSEN OLE ANDREAS
Shares: 8,729,345 · Class: 9.99%
- Ott David C.
Shares: 8,729,345 · Class: 9.99%
- Shabet Rose Sharon
Shares: 8,729,345 · Class: 9.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000905148-25-002996
- Form type
- SCHEDULE 13G/A
- Filer
- Oric Pharmaceuticals, Inc.
- CIK
- CIK 1796280
- Filed
- Aug 14, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership